Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN.

Front Oncol. 2018 Nov 19;8:463. doi: 10.3389/fonc.2018.00463. eCollection 2018.

2.

A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.

Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J.

Eur Urol. 2014 Sep;66(3):529-41. doi: 10.1016/j.eururo.2014.03.003. Epub 2014 Mar 16. Review.

PMID:
24680361
3.

Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.

Buisan O, Orsola A, Areal J, Font A, Oliveira M, Martinez R, Ibarz L.

Clin Genitourin Cancer. 2017 Feb;15(1):145-151.e2. doi: 10.1016/j.clgc.2016.05.004. Epub 2016 Jun 1.

PMID:
27364982
4.

Adjuvant chemotherapy is possibly beneficial for locally advanced or node-positive bladder cancer.

Kanatani A, Nakagawa T, Kawai T, Naito A, Sato Y, Yoshida K, Nozaki K, Nagata M, Yamada Y, Azuma T, Suzuki M, Fujimura T, Fukuhara H, Nishimatsu H, Kume H, Igawa Y, Homma Y.

Clin Genitourin Cancer. 2015 Apr;13(2):e107-12. doi: 10.1016/j.clgc.2014.09.007. Epub 2014 Nov 6.

PMID:
25456839
5.

Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.

Lane G, Risk M, Fan Y, Krishna S, Konety B.

BJU Int. 2019 May;123(5):818-825. doi: 10.1111/bju.14529. Epub 2018 Sep 17.

PMID:
30126053
6.

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.

Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ.

World J Urol. 2016 Nov;34(11):1567-1573. Epub 2016 Apr 12.

PMID:
27072536
7.

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.

Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ.

Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6. Review.

8.

Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.

Reardon ZD, Patel SG, Zaid HB, Stimson CJ, Resnick MJ, Keegan KA, Barocas DA, Chang SS, Cookson MS.

Eur Urol. 2015 Jan;67(1):165-170. doi: 10.1016/j.eururo.2014.01.009. Epub 2014 Jan 23.

9.

Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.

Koie T, Ohyama C, Yamamoto H, Hatakeyama S, Imai A, Yoneyama T, Hashimoto Y, Kitayam M, Hirota K.

Urol Oncol. 2014 Aug;32(6):820-5. doi: 10.1016/j.urolonc.2014.03.010. Epub 2014 Jun 18.

PMID:
24951323
10.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.

Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Théodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A; RISC Investigators.

Eur Urol. 2019 Oct;76(4):425-429. doi: 10.1016/j.eururo.2019.06.032. Epub 2019 Jul 11.

PMID:
31303258
11.

Impact of neoadjuvant chemotherapy on complications of minimally invasive radical cystectomy.

Lizée D, Salas RS, Barret E, Galiano M, Di Trapani E, Montorsi F, Cathelineau X.

Actas Urol Esp. 2017 Mar;41(2):88-96. doi: 10.1016/j.acuro.2016.05.008. Epub 2016 Nov 28. English, Spanish.

PMID:
27908636
12.

The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study.

Kaiser J, Li H, North SA, Leibowitz-Amit R, Seah JA, Morshed N, Chau C, Lee-Ying R, Heng DYC, Sridhar S, Crabb SJ, Alimohamed NS.

Bladder Cancer. 2018 Apr 26;4(2):185-194. doi: 10.3233/BLC-170133.

13.

Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study.

Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, Berman DM, Mackillop WJ.

Cancer. 2014 Jun 1;120(11):1630-8. doi: 10.1002/cncr.28510. Epub 2014 Apr 14.

14.

Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.

Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ.

Cancer. 2009 Feb 15;115(4):792-9. doi: 10.1002/cncr.24106.

15.

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion.

Eldefrawy A, Soloway MS, Katkoori D, Singal R, Pan D, Manoharan M.

Indian J Urol. 2012 Oct;28(4):424-6. doi: 10.4103/0970-1591.105756.

16.

Neoadjuvant chemotherapy improves survival rate in advanced urothelial carcinoma.

Tsai CC, Huang CH, Huang CN, Wu WJ, Yeh HC, Li WM, Li CC, Lee MH.

Kaohsiung J Med Sci. 2013 Apr;29(4):200-5. doi: 10.1016/j.kjms.2012.08.034. Epub 2012 Dec 21.

17.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC; RISC Investigators.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30001-X. doi: 10.1016/j.euo.2018.12.013. [Epub ahead of print]

PMID:
31411990
18.

Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.

Seah JA, Leibowitz-Amit R, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM, Sridhar SS.

Clin Genitourin Cancer. 2015 Aug;13(4):e229-e233. doi: 10.1016/j.clgc.2015.02.001. Epub 2015 Feb 7.

PMID:
25777682
19.

The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.

Bruins HM, Aben KK, Arends TJ, van der Heijden AG, Witjes AJ.

Urol Oncol. 2016 Apr;34(4):166.e1-6. doi: 10.1016/j.urolonc.2015.11.006. Epub 2015 Dec 15.

PMID:
26705102
20.

Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.

Ozcan MF, Dizdar O, Dincer N, Balcı S, Guler G, Gok B, Pektas G, Seker MM, Aksoy S, Arslan C, Yalcin S, Balbay MD.

Urol Oncol. 2013 Nov;31(8):1709-15. doi: 10.1016/j.urolonc.2012.06.014. Epub 2012 Aug 3.

PMID:
22863869

Supplemental Content

Support Center